Product Description
Mechanisms of Action: HCV-NS5A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Hepatitis A|Hepatitis C
Phase 1: Kidney Diseases|Healthy Volunteers|Hepatitis A|Hepatitis C, Chronic|Communicable Diseases|Hepatitis C
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02961660 |
CR108242 | P1 |
Completed |
Kidney Diseases |
2018-04-09 |
19% |
2019-03-21 |
Treatments |
NCT03059303 |
CR108273 | P1 |
Terminated |
Healthy Volunteers |
2017-04-24 |
2019-03-21 |
Treatments |
|
NCT02889367 |
CR108163 | P1 |
Completed |
Healthy Volunteers |
2017-03-04 |
2019-03-20 |
Treatments |
|
NCT02945020 |
CR108164 | P1 |
Completed |
Healthy Volunteers |
2017-01-09 |
2019-03-21 |
Treatments |
|
NCT02885454 |
CR108177 | P1 |
Completed |
Healthy Volunteers |
2016-12-01 |
2019-03-20 |
Treatments |
|
NCT02824315 |
CR108179 | P1 |
Completed |
Healthy Volunteers |
2016-10-01 |
2019-03-20 |
Treatments |
|
NCT02821858 |
CR108178 | P1 |
Completed |
Healthy Volunteers |
2016-09-09 |
2019-03-20 |
Treatments |
|
NCT02512562 |
AL-335-602 | P1 |
Completed |
Hepatitis C, Chronic |
2015-08-31 |
2023-11-01 |
Primary Endpoints|Treatments |
|
ACTRN12614000102673 |
ACH786-Â001 | P1 |
Completed |
Hepatitis C |
2014-02-28 |
2024-08-29 |
Treatments |
|
NCT01700179 |
ACH102-005 | P1 |
Completed |
Communicable Diseases|Hepatitis A|Hepatitis C, Chronic |
2013-09-01 |
2023-11-01 |
Primary Endpoints|Treatments |
|
NCT02569710 |
AL-335-604 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
44% |
2019-03-20 |
Treatments |
2016-002845-46 |
2016-002845-46 | P2 |
Completed |
Hepatitis C, Chronic |
2018-05-11 |
2022-03-13 |
Treatments |
|
NCT02993250 |
CR108264 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2018-05-07 |
54% |
2019-03-22 |
Treatments |
2015-004200-38 |
2015-004200-38 | P2 |
Completed |
Hepatitis C, Chronic |
2017-11-16 |
2022-03-13 |
Treatments |
|
NCT02765490 |
CR108070 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2017-08-09 |
2019-03-20 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
ACTRN12614000307606 |
ACTRN12614000307606 | P2 |
Completed |
Hepatitis C |
2015-04-09 |
2024-08-29 |
Treatments |
|
NCT01849562 |
ACH102-007 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-11-01 |
2023-11-01 |